Key facts
- BMI OrganBank’s last known valuation is $18.0M (Mar 2024).
- It has raised $4.0M; the latest was Early Stage VC ($6.0M) in Mar 2024.
- Notable investors include National Institutes of Health, Band of Angels, First Flight Venture Center, Golden Seeds, Mid Atlantic Bio Angels — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for BMI OrganBank
- ·The full record, as it builds
Funding rounds
No funding rounds for BMI OrganBank are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BMI OrganBank
Developer of a portable kidney preservation platform designed to maintain physiological function during organ transport and evaluation. The company offers a room-temperature preservation system that sustains kidneys in an oxygenated, pulsatile state and enables functional assessment during transport, enabling transplant centers and organ procurement organizations to evaluate organ function and support clinical decision-making during preservation.
- Sector
- Healthcare
- HQ
- Denver, NC, United States
- Employees
- 11
- Website
- bmiorganbank.com/
- Ownership
- Privately Held (backing)
BMI OrganBank doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BMI OrganBank shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BMI OrganBank in its N-PORT filings yet. We sweep new filings monthly.